Medical device maker Boston Scientific said it swung to a third-quarter loss, as legal fees and restructuring expenses weighed down already-sluggish sales of the company’s implants. The Natick company adjusted its full-year guidance. It now expects adjusted earnings of 63 to 66 cents per share. Its prior forecast was 62 to 68 cents. For the quarter, it lost $725 million, or 52 cents per share, compared with a profit of $142 million, or 9 cents, a year earlier.
Boston Scientific posts loss
You've reached the limit of 10 free articles a month
Stay informed with unlimited access to Boston’s trusted news source.
- High-quality journalism from the region’s largest newsroom
- Convenient access across all of your devices
- Today’s Headlines daily newsletter
- Subscriber-only access to exclusive offers, events, contests, eBooks, and more
- Less than $1 a week